Dr. Jain on the Role of Allogeneic Transplant in Myelofibrosis

Partner | Cancer Centers | <b>Johns Hopkins Cancer Center</b>

Tania Jain, MBBS, discusses the role of allogeneic stem cell transplant in myelofibrosis.

Tania Jain, MBBS, assistant professor of oncology, Division of Hematological Malignancies and Stem Cell Transplantation, Johns Hopkins University, discusses the role of allogeneic stem cell transplant (allo-SCT) in myelofibrosis.

Currently, allo-SCT is the only curative-intent treatment for patients with myelofibrosis, says Jain. Drugs like ruxolitinib (Jakafi) and fedratinib (Inrebic) may offer symptom management and reduction in spleen size. However, they do not alter the natural history of the disease.

Patients with intermediate-2 and high-risk myelofibrosis according to the Dynamic International Prognostic Scoring System (DIPSS)-plus scoring system or those with transfusion-dependence complications should be considered for allo-SCT. Other factors that may influence transplant eligibility include age and organ function, says Jain.

Additionally, the Mutation-Enhanced International Prognostic Scoring System (MIPSS)70 and MIPSS70-plus version 2.0 scoring system may offer prognostic information that could shed additional light on transplant eligibility, concludes Jain.